Full-Time

Maintenance & Utilities Technician I

Posted on 7/16/2026

Kyowa Kirin

Kyowa Kirin

1,001-5,000 employees

Global specialty pharma focused on antibodies

Compensation Overview

$26.63 - $32.55/hr

+ Annual Bonus Program + Long-Term Incentive Program

Sanford, NC, USA

In Person

On-site role at Sanford, NC facility; 5% travel domestic.

Bachelor's, Associate's, Certification

Category
Building Systems & HVAC (2)
,
Required Skills
Process Engineering
FDA Regulations

Get referred to Kyowa Kirin

See people who can refer or advise you

Requirements
  • High School diploma or equivalent.
  • 0-2 years relevant maintenance experience.
Responsibilities
  • With supervision be able to perform scheduled inspections and maintenance on bioprocessing equipment (e.g., bioreactors, centrifuges, filtration units).
  • With supervision be able to perform preventive and corrective maintenance on boilers, chillers, air compressors, WFI water systems, HVAC, and other utilities as required.
  • With assistance, diagnose equipment malfunctions and conduct timely repairs.
  • Provides support for start-up, commissioning and turnover of new systems throughout the site.
  • Maintain accurate records for audits, in compliance with GMP (Good Manufacturing Practices) and FDA regulations.
  • Work closely with process engineers, quality assurance, and manufacturing staff.
  • Document root causes and assist in finding long-term solutions.
Desired Qualifications
  • Associates or Bachelor’s degree in a related field is a plus.
  • Completion of the BioWork certification program with the North Carolina Community College System is considered a plus.
  • 1+ years’ experience within a GMP and/or other highly regulated environment highly desirable.
  • Demonstrates a growth mindset and ability to adapt to change with clarity, patience, and professionalism.

1) What does this company do? Kyowa Kirin develops specialty pharmaceutical drugs with a focus on nephrology, oncology, and immunology, built on a foundation of fermentation technology and antibody science. 2) How does this company's product(s) work? It uses fermentation-derived biology and antibody-based approaches to create therapies that target kidney disease, cancer, and immune-related conditions, delivered as approved medicines after research, development, and clinical testing. 3) How is this company different from its competitors? It blends deep fermentation and microbiology expertise with antibody technology from its history, plus a global specialty-drug focus, resulting from a merger of Kyowa Hakko Kogyo and Kirin Pharma that combined fermentation know-how with pharmaceutical resources. 4) What is this company's goal? To develop and commercialize innovative treatments that address unmet medical needs in nephrology, oncology, and immunology on a global scale.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Get referred to Kyowa Kirin

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Kyowa Kirin won FDA PreCheck on June 30, 2026 for Sanford construction.
  • Ziftomenib Phase 2 in Japan started April 24, 2026, expanding KOMZIFTI beyond America.
  • Cimeio partnership and Orchard's Japan orphan designation deepen cell and gene therapy optionality.

What critics are saying

  • Rocatinlimab trials ended March 2026 after malignancy concerns, damaging pipeline confidence and timelines.
  • Amgen exited rocatinlimab in January 2026, forcing Kyowa Kirin to shoulder regulatory and commercial risk.
  • Sanford's 2027 plant startup and FDA PreCheck still leave manufacturing execution risk unresolved.

What makes Kyowa Kirin unique

  • Kyowa Kirin combines 70 years of antibodies, fermentation, and rare-disease expertise.
  • Orchard Therapeutics adds one-shot HSC gene therapy, a modality few Japanese pharma companies own.
  • KOMZIFTI launched in November 2025, giving Kyowa Kirin U.S. oncology commercialization credibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

Paid Vacation

Paid Sick Leave

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Hybrid Work Options

Pet Insurance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-2%
Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding

Cimeio Therapeutics
Dec 10th, 2024
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies

The partnership combines Cimeio's proprietary Shielded Cell and Immunotherapy (SCIP) platform with Kyowa Kirin's expertise in cellular therapies and underscores both companies' commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients.

Business North Carolina
Nov 27th, 2024
Op/ed: Biotech's role in North Carolina's job-creation success

Kyowa Kirin, a Japanese global specialty pharmaceutical company, plans to invest more than $200 million in Sanford to build its first pharmaceutical manufacturing complex in North America, adding more than 100 new jobs.

World Pharmaceutical Frontiers
Jun 11th, 2024
Kyowa Kirin to establish new $530m biologics manufacturing plant in US

Japan-based Kyowa Kirin has unveiled its plans to invest $530m to build a new advanced biologics manufacturing facility in Sanford in the American state of North Carolina.

INACTIVE